Skip to main content
MIT to develop programmable cell therapies with Sigilon
1/21/2019

MIT has entered a collaborative partnership with Sigilon Therapeutics to create programmable cell therapeutics to treat chronic illnesses and diseases such as hemophilia and lysosomal storage diseases.

Full Story: